Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2021 | Molecular testing for adenocarcinoma and squamous cell lung cancer

Sonam Puri, MD, Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT, discusses the testing procedures for the two types of non-small cell lung cancer (NSCLC). Dr. Puri speaks on the value of broad-based DNA/RNA molecular testing on any patient with metastatic adenocarcinoma at the time of diagnosis. However, this testing is limited for patients with early-stage disease. For squamous cell lung cancer, a PD-L1 test is conducted which acts as a biomarker for immunotherapy response. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.